DiaSorin (DSRLF) Stock Price, News & Analysis

Company Overview

DiaSorin S.p.A. is an Italian healthcare company that develops, manufactures and markets in vitro diagnostic products. Its portfolio is focused on immunodiagnostics and molecular diagnostics used to support the detection and monitoring of diseases and medical conditions.

The company offers diagnostic assays, reagents and analytical systems for areas including infectious diseases, endocrinology, oncology, autoimmune disorders, bone and mineral metabolism, cardiovascular conditions and gastrointestinal diseases. Its product portfolio includes the LIAISON family of automated immunodiagnostic platforms, as well as molecular testing solutions and multiplexing technologies obtained through its acquisition of Luminex.

DiaSorin serves hospitals, clinical laboratories, physicians and other healthcare providers internationally through direct operations and distribution networks. The company traces its origins to 1968 and is headquartered in Saluggia, Italy. Carlo Rosa has served as DiaSorin’s chief executive officer and is associated with the company’s long-term leadership.

Key Stats

• Today's Range: $84.00 to $84.00
• 50-Day Range: $81.00 to $86.00
• 52-Week Range: $66.50 to $100.00
• Volume: N/A
• Average Volume: 0 shs
• Market Capitalization: $4.60 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Strong Sell

DiaSorin Stock Analysis - MarketRank™

DiaSorin scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Strong Sell

Consensus Rating

DiaSorin has received a consensus rating of Strong Sell. The company's average rating score is 1.40, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 3 sell ratings.

Amount of Analyst Coverage

DiaSorin has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 14.45%

Earnings Growth

Earnings for DiaSorin are expected to grow by 14.45% in the coming year, from $4.29 to $4.91 per share.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.20% of the float of DiaSorin has been sold short.

Short Interest Ratio / Days to Cover

DiaSorin has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DiaSorin has recently decreased by 4.71%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DiaSorin does not currently pay a dividend.

Dividend Growth

DiaSorin does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

DiaSorin has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, DiaSorin insiders have not sold or bought any company stock.

Percentage Held by Institutions

DiaSorin has minimal institutional ownership at this time.

Company Calendar

• Today: 10/07/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:DSRLF
• CIK: N/A
• Web: www.diasoringroup.com
• Phone: 391614871
• Fax: N/A
• Employees: 3,249
• Year Founded: 1968

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.28 billion
• Price / Sales: 3.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 54,710,000
• Free Float: N/A
• Market Cap: $4.60 billion
• Optionable: Not Optionable
• Beta: 0.37